CashPool is a new mobile platform that gives everyday investors the opportunity to derive influence from the investment strategies and trades made by trusted and influential stock traders. Photo via joinmypool.co

As anyone who witnessed the impact Gamestop's meme stock had on the country already realizes, influential investors can drive momentum within the financial sector. And one company with fresh funding from a Houston firm is betting on that exactly.

CashPool is a new mobile platform that gives everyday investors the opportunity to derive influence from the investment strategies and trades made by trusted and influential stock traders who have built substantial followings on social media platforms. By allowing retail traders the chance to join social media influencers’ various “pools” on its platform, CashPool is primed to change the way the masses acquire wealth.

This is the kind of algorithmic trading aimed at a new generation of investors that gets the attention of early-stage venture capital funds like Houston-based Ten X Labs, a pre-seed angel fund that recently invested in CashPool to help the trading platform continue its mission of transforming the investment landscape.

"We are thrilled to receive funding from Ten X Labs, as it validates our innovative approach to trading and investing," CashPool Founder and CEO Averett Barksdale says in a news release. "This investment will enable us to further enhance our platform, expand our user base and continue to revolutionize the industry. We believe that everyone should have transparent, governed access to profitable trading and investment opportunities, and through CashPool we are making that vision a reality."

Connecting the dots

CashPool is broker agnostic connector, allowing its users to keep their current brokers like Robinhood, Coinbase, Charles Schwab, Acorns, Fidelity, ETRADE, Stash, Sofi and Betterment and creates a seamless investment experience.

“We are that middle piece,” says Barksdale. “So your money stays on whatever brokerage you’ve connected to the platform, and we just execute the trades on your brokerage for you.”

Considering that users’ money remains with their original brokerage, how does CashPool monetize its platform?

“We don’t charge users to execute trades,” says Barksdale. “We charge per pool you join. So, on our platform, strategies are called pools and a user can join as many strategies as they want.”

Financial influencers set the strategies. These are profitable traders who have become influencers on various social media platforms and built-up followings comprised of people who are or are desiring to be retail traders themselves.

“There are a ton of people out there who actually are profitable traders,” says Barksdale. “Same as what we saw happen with GameStop and the whole Reddit situation. That was a financial influencer, right? It just so happens that he had a strategy that he thought would work and it turned out for a while it did work, right?

“We want to not only empower the retail trader, but empower these financial influencers who are profitable as well. Just because it's a whole marketplace out there for it. But a lot of times the retail trader doesn't quite understand who to go with. On our platform, you could see the results of these financial influencers right before your eyes on our platform. So you can see if they're profitable or not, or if someone's just on Instagram or whatever, social media platform posting screenshots but aren’t actually executing those trades.”

Increasing transparency

With trading, past success can be an arbiter for future performance, so with CashPool, users can choose to join the pools of influencers who have documented success as a trader on the platform.

“On our platform you can't hide,” says Barksdale. “We're connected to their brokerage account, so we see what trades they're making in real time. We also see their performance in real time, and we display that on the platform. That's something that you really can't get around. So if someone on Instagram says they traded this stock, then I made X amount of dollars and had this percentage of return, then you go to the platform and look at your pool and see they didn't do that and were lying the whole time, it’s literally just putting everything out there in the open. We have the kind of transparency that doesn't exist currently right now in the space.”

Broadcasting one’s successes is easy, but what about the losses?

“I thought it was going to be a lot more difficult just thinking, do people really want to show what they're doing?” says Barksdale. “But the thing that I've seen is a lot of these traders are a whole lot more competitive. And the traders who are doing it, they're constantly talking out against people who aren't actually doing it in real life.

“A lot of the traders who are actually profitable, they do live trades every day. But how do users if they should pay to get into a specific trader’s live trading session? Like, how do they know they're profitable already?

“On CashPool, users can see an actual influencer's win rate and say, 'Okay, 86 percent of the time they are profitable, and I could see how many trades they've made in total.' From that standpoint, users can make an educated decision on what pools to join and pay for.”

CashPool users can join as many pools as they see fit, but the cost of each pool’s membership may vary due to the popularity or success percentage rate of the financial influencer.

“You can join as many pools as you want, but what we suggest is you start by joining the pools of influencers that you already follow and trust, that you're already following like on Twitter or YouTube or Instagram or whatever it may be,” says Barksdale. “We are suggesting that you follow them first and you join their pools first. What we do is on the monetization side is we allow the creators on our platform who are the influencers to set their own price for their pool.”

Building a secure network

Outside of who or what to follow, information security is likely a concern for potential users. Financial influencers’ trade information is readily available (win percentages and number of trades, not dollar amounts), but users’ won’t be able to see other users’ information on the platform.

“Currently, we have a list of 10 brokerages who are on board, and then we're working to onboard more as we keep going on,” says Barksdale. “So, we have like your Interactive brokerages, and we also have a few other ones that are UK specific and Canada specific. We would love to have every single brokerage on the platform, but unfortunately, there are a couple that are still kind of playing hard to get, so to speak.”

The first rollout of CashPool is set, but version two will likely include content creation from the financial influencers.

Barksdale, who has a background in product development and experience working at companies like Charles Schwab and Fidelity, is mostly excited about the prospect of CashPool unlocking expert financial strategies for everyone, not just the financial advisors behind the closed doors of Wall Street.

“Yes, my philosophy is that financial health and financial growth should be accessible for all,” says Barksdale. “The thing that gets me is it needs to be responsible. So, for example, RobinHood is a platform that doesn't necessarily care if you are making responsible decisions, they just care that you're trading on that platform.

“Our platform is strictly focused on actually being the place where these retail traders can make responsible decisions centered around investing and trading.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Top stories: Houston's most-read health tech news of 2024

year in review

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In the health tech category on InnovationMap, top stories included startup funding raised, IPO plans, FDA clearance, and more. Be sure to click through to read the full story.

New report ranks Houston top market for life sciences

Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. Photo by Natalie Harms/InnovationMap

Thanks in large part to producing hundreds of college-trained professionals, Houston’s life sciences industry ranks among the top U.S. markets for talent in 2024.

In a report published by commercial real estate services company CBRE, Houston lands in the No. 7 spot for growth in the granting of degrees in biological and biomedical sciences. From 2017 to 2022, Houston notched a growth rate of 32.4 percent in this category.

In 2022, the University of Houston led the higher education pack in the region, graduating 746 people with a bachelor’s degree or above in biological or biomedical sciences, according to the report. Continue reading.

Houston innovator raises pre-seed funding for health care staffing platform

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. Photo courtesy of Lokum

A Houston health care innovator is celebrating an oversubscribed round of pre-seed funding to improve on her startup's unique staffing platform.

Ayoade Joy Ademuyewo founded Lokum last year to create a solution to better connecting medical specialists with health care facilities nationwide. The new platform, which cuts out the middleman and lowers staffing costs, raised $700,000 in pre-seed funding that will go toward further development of the technology.

"Healthcare organizations spend $26 billion annually to support a crippling dependence on third-party agencies for connecting with clinical staff," Ademuyewo says in a news release. "Technological solutions that are pointed precisely to streamline and strengthen the relationships between highly specialized clinicians and their future employers are vital to alleviating this detrimental dependance, and central to our mission." Continue reading.

Houston regenerative medicine company to IPO, move toward more human trials

FibroBiologics will IPO this week. Photo via Getty Images

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.” Continue reading.

Houston organizations identify promising life science cos. at annual event

The Rice Alliance and BioHouston acknowledged innovations from a dozen promising health tech companies. Photo via Rice University

For the 13th year, the Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship celebrated innovative companies from around the world that are creating new treatments and solutions to today's biggest health care challenges.

This week, over 40 companies presenting their innovations across cancer, cardiovascular disease, biotechnology, and more. Nearly 700 venture capitalists, corporate innovation groups, angel networks, industry leaders, academics, service providers, and others attended the event on November 7 at Rice's BioScience Research Collaborative in the Texas Medical Center.

Just like in previous years, the event ended with the announcement of the 10 companies that were deemed "most promising" based on their pitches and technologies. Of the 10 companies named, six are headquartered in Houston and an additional two startups on the list have a presence here. Continue reading.

FDA greenlights Houston surgery robotics company's unique technology

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

Houston billionaire Tilman Fertitta nominated as ambassador to Italy

foreign affairs

Houston billionaire and Rockets owner Tilman Fertitta has been nominated to serve as the United States ambassador to Italy, according to U.S. President-elect Donald Trump.

On Saturday, Trump sent the following statement via Truth Social Post:

"I am pleased to announce that Tilman J. Fertitta has been nominated to serve as the United States Ambassador to Italy. Tilman is an accomplished businessman, who has founded and built one of our Country's premier entertainment and real estate companies, employing approximately 50,000 Americans. Tilman has a long history of giving back to the community through numerous philanthropic initiatives, which include children's charities, Law Enforcement, and the medical community. Additionally, Tilman is the longest serving Chairman of the Board of Regents for the University of Houston. He also owns the Houston Rockets Basketball Team. Congratulations to Tilman, and his remarkable family!"

Fertitta, 67, also is the chairman, CEO, and president of Landry's Inc. and the chairman of the University of Houston's board of regents.

"It is an honor to be nominated to serve my country as ambassador to Italy and I look forward to the process ahead. Italy is such an extraordinary country with its wonderful people, culture, and history and its strategic importance to The United States of America," Fertitta said.

---

Read the full story on CultureMap's news partner, ABC13.com.

Houston biotech biz to merge with public co., set local HQ

big deal

Houston-based Tvardi Therapeutics and Cara Therapeutics announced the companies have entered into a definitive merger agreement to combine in an all-stock transaction. Once completed, Houston will house the headquarters.

Tvardi is a clinical-stage biopharmaceutical company that focuses on the development of novel, oral, and small molecule therapies that target STAT3 to treat fibrosis-driven diseases. Tvardi will merge with a wholly owned subsidiary of Cara.

Once complete, the pre-merger Cara Therapeutics stockholders are expected to own approximately 17 percent of the combined company and pre-merger Tvardi Therapeutics investors are expected to own 83 percent of the combined company. Prior to adjustment from the issuance of the shares in the recently completed Tvardi financing and assuming Cara, which went public in 2014, has net cash at closing of between $22.9 million and $23.1 million with the percentage of the combined company that pre-merger Cara stockholders and pre-merger Tvardi stockholders will own upon the closing of the merger, which is subject to further adjustment if Cara’s net cash balance falls outside of the range.

“As we approach meaningful value inflection points next year, including two Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis, followed by the readout in our hepatocellular carcinoma program, this merger, the recently completed financing, and becoming a publicly traded company give us access to the critical funding required to further advance our promising pipeline programs that address significant unmet needs,” Imran Alibhai, CEO of Tvardi Therapeutics, says in a news release.

Also, Tvardi has completed an approximately $28 million private financing from a syndicate of new and existing institutional investors. With the cash from both companies at closing and the proceeds of this financing, the post-merger company plans to have cash to fund its operating expenses and capital expenditure requirements into the second half of 2026.

“I am grateful to the Cara Board, leadership team, and shareholders who share our vision of Tvardi that is well-positioned to introduce effective, new treatment options to patients suffering from serious, chronic, fibrosis-driven diseases,” Alibhai continues.

In 2021, Tvardi emerged from stealth and closed a $74 million series B funding round led by New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.